diabetes

Why Sugar Is Suing High Fructose Corn Syrup

When you need to give yourself a whole new image, there's nothing like changing your name. Which may be why high fructose corn syrup, the scourge of dieticians and dieters everywhere, wants to rebrand itself "corn sugar." But there's one big obstacle: the sugar industry, which is going to court to protect its good name.

Big Pharma Looks Beyond Drugs to Smartphone Apps

Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.

As Diabetes Explodes, Big Pharma Is Gearing Up

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver. As the number of people with diabetes and prediabetes explodes, drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

The Number of Americans With Diabetes Is Projected to Soar

As many as one-third of American adults could develop diabetes in the next 40 years, according to a new analysis by the Centers for Disease Control and Prevention (CDC). Diabetes was the seventh leading cause of death in 2007, and it's the leading cause of new cases of blindness among adults under age 75, according to the CDC report. The disease is also among the most expensive chronic illnesses to treat, and is considered one of the culprits in rising health care costs.

'Fructose-Slurping' Cancer Could Sour the Soda Business

Soda and processed-food makers insist that all sugars are the same. Yet with studies linking high fructose corn syrup to obesity, diabetes and, most recently, pancreatic cancer, big brands are quietly backing away from using the corn-based sweetener.

MannKind Shares Soar on Good News From FDA

MannKind shares jumped about 10% in afternoon trading after the pharmaceutical company announced the Food and Drug Administration accepted its resubmission of its inhaled insulin, Afrezza. The FDA set a review date for Dec. 29.

FDA Panel Votes to Keep Avandia on Market

GlaxoSmithKline's diabetes drug Avandia has been found to have increased heart attack risk compared to other similar medication. But a majority of the Food and Drug Administration's panel of outside experts have voted to keep the drug on the market -- though new restrictions are likely.

FDA Panel Scrutinizing Diabetes Drug Avandia

On Tuesday, the FDA will convene a panel of experts to discuss GlaxoSmithKline's type II diabetes drug Avandia. Once a blockbuster, sales of the drug have dropped by more than half since studies suggested it significantly increases risk for serious heart problems.

Avandia Linked to Heart Attacks in Two New Studies

GlaxoSmithKline's diabetes drug Avandia once again captured headlines Monday morning after two new studies linked it to heart attacks and other cardiovascular complications. The authors of the studies say the results should prompt the FDA to pull the drug from the market.

Amylin Shares Jump as Roche Delays Diabetes Drug

Pharmaceutical giant Roche said Friday that it would delay an FDA filing for its new diabetes drug for 12 to 18 months due to safety concerns. The beneficiary of Roche's misfortune is rival Amylin, which now jumps ahead in the race to get first approval of a once-weekly injectable type 2 diabetes drug.

Four Trends That Will Dramatically Change China

The financial media's coverage of China tends to focus on trade-related topics, but China is undergoing deep cultural shifts that will dramatically alter its economic landscape. These four long-term trends could drastically change China -- and its relationship with the world.

FDA May Halt Safety Study on Diabetes Drug Avandia

The FDA is considering halting a safety study on GlaxoSmithKline's diabetes drug Avandia, The Wall Street Journal reported Sunday. Previous studies have linked Avandia to an increased risk of heart attacks. The implication is a serious threat to the continued sale of Avandia in the U.S.

Drug Approval Lifts Novo Nordisk, Amylin Stock

Federal regulators approved Novo Nordisk's new once-daily injection for treating Type 2 diabetes Victoza, driving shares higher. Shares of Amylin Pharmaceuticals also rallied as the approval of Victoza raises hopes that Amylin's rival drug will also get the greenlight.

Dialysis Firm DaVita 'Nervous' About Reform

While DaVita says health reform would allow the dialysis-center operator to offer more integrated care, it could hurt business if Medicare recipients become an even bigger part of its patient load. CEO Kent Thiry reviews the pros and cons of reform.

Health Reform Leaves Millions Uninsured

While many politicians trumpet the increased insurance coverage in the health-reform legislation, the bill the Senate will soon vote on still leaves 23 million uninsured. What's more, neither the Senate nor the House version of the reform takes effect before 2013, leaving many uninsured without relief for years.

Roche Diabetes Drug Makes Waves

The U.S. diabetes drug market just got a little more competitive. Swiss drugmaker Roche (RHHBY) said Wednesday an experimental medicine in late-stage development works better in treating type 2 diabetes than Merck (MRK) Januvia, according to a clinical study.